OMER Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Omeros Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.03 |
| 52 Week High | US$7.51 |
| 52 Week Low | US$1.66 |
| Beta | 1.48 |
| 11 Month Change | 47.07% |
| 3 Month Change | 46.36% |
| 1 Year Change | 235.00% |
| 33 Year Change | -22.69% |
| 5 Year Change | -57.95% |
| Change since IPO | -30.93% |
Recent News & Updates
Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns
Nov 17Omeros: Troubled Company Working Its Way Out Of The Morass
Jul 19Recent updates
Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns
Nov 17Omeros: Troubled Company Working Its Way Out Of The Morass
Jul 19Omeros: Still Worth A Look Despite Narsoplimab Woes
Feb 14Is Omeros (NASDAQ:OMER) A Risky Investment?
Jul 26
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Mar 17Omeros: Taking It To The Max
Oct 05Omeros falls 11% after reporting clinical data for COVID-19 therapy
Sep 15Omeros: Managing An Investment After A Winning Trade
Aug 16Omeros granted FDA’s Orphan Drug designation for PNH candidate
Jul 28Omeros: Follow The Bouncing Ball
Jul 04Omeros: On Death's Door
Jun 02Omeros: The Weight Of The Wait, A Conundrum
May 03Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Feb 21Omeros: A New Year Beckons
Dec 06Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates
Dec 04Omeros: What's Left
Oct 15Omeros: The Prize Is Nigh (Again)
Sep 14Omeros: PDUFA Delay Presents An Opportunity
Jul 03Omeros posts preliminary results from early-stage OMS906 trial
Jun 09Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?
Jun 05Omeros posts preliminary results from COVID-19 patients treated with narsoplimab
May 28CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab
May 04Shareholder Returns
| OMER | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 43.9% | -5.3% | -1.2% |
| 1Y | 235.0% | 8.7% | 30.4% |
Return vs Industry: OMER exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: OMER exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| OMER volatility | |
|---|---|
| OMER Average Weekly Movement | 19.8% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OMER's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OMER's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 198 | Greg Demopulos | www.omeros.com |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders.
Omeros Corporation Fundamentals Summary
| OMER fundamental statistics | |
|---|---|
| Market cap | US$349.44m |
| Earnings (TTM) | -US$185.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs OMER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMER income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$69.78m |
| Gross Profit | -US$69.78m |
| Other Expenses | US$115.60m |
| Earnings | -US$185.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -268.2% |
How did OMER perform over the long term?
See historical performance and comparison